Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sanguisorba officinalis aglycone lipidosome, and preparation method and purpose thereof

A technology of elmia aglycone lipid and fructus aglycone, which is applied in the field of medicine and can solve the problems such as restricting the application of fructus aglycone, poor medicinal effect of fructus aglycone, increasing blood cell level and the like

Inactive Publication Date: 2017-04-26
SICHUAN YINGLU WEITE PHARMA TECH CO LTD
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In actual use, it was found that the efficacy of burnet aglycone is not good. When used alone, it can increase the blood cell level and treat bone marrow suppression, which greatly limits the clinical application of burnet aglycone.
[0006] At present, there is no public report on the preparation of liposomes with saponin from Burnet as the active ingredient for the treatment and / or prevention of myelosuppression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sanguisorba officinalis aglycone lipidosome, and preparation method and purpose thereof
  • Sanguisorba officinalis aglycone lipidosome, and preparation method and purpose thereof
  • Sanguisorba officinalis aglycone lipidosome, and preparation method and purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] The preparation of embodiment 1 liposome of the present invention

[0029] Prescription 1 (A): Burnet aglycone 1mg, HSPC 1mg, DSPE-PEG 2000 10mg, cholesterol 10mg, glucose 1mg;

[0030] Prescription 2 (B): Burnet aglycone 1mg, HSPC 5mg, DSPE-PEG 2000 30mg, cholesterol 3mg, sucrose 3mg;

[0031] Prescription 3 (C): Burnet aglycone 2mg, HSPC 5mg, DSPE-PEG 2000 20mg, cholesterol 10mg, trehalose 3mg;

[0032] Prescription 4 (D): Burnet aglycone 5mg, HSPC 10mg, DSPE-PEG 2000 30mg, cholesterol 30mg, fructose 5mg;

[0033] Prescription 5 (E): 7mg of Sanyu aglycone, 10mg of HSPC, 40mg of DSPE-PEG 2000, 50mg of cholesterol, 5mg of mannose;

[0034] Prescription 6 (F): Burnet aglycone 10mg, HSPC 10mg, DSPE-PEG 2000 40mg, cholesterol 50mg, lactose 5mg.

[0035] Prescription 7 (G): 1 mg of eucalyptus aglycone, 20 mg of carrier material (HSPC: DSPE-PEG 2000: cholesterol = 5: 1: 1, ie 14 mg of HSPC, 3 mg of DSPE-PEG 2000, 3 mg of cholesterol), 5 mg of sucrose.

[0036] Preparatio...

experiment example 1

[0040] Experimental example 1 adopts the quality evaluation of different carrier materials to prepare buretin liposome

[0041] There are 7 experimental groups in this experiment.

[0042] Mix 1 mg of burnet aglycone with different carrier materials HSPC, DSPE-PEG 2000, cholesterol, lecithin, and stigmasterol mixed lipids according to the mass ratio of 1:20, dissolve in ethanol, remove ethanol by rotary evaporation under reduced pressure, and add 5 mg Sucrose and water, so that the concentration of eucalyptin in the liposome suspension is 0.2 mg / mL, high-pressure homogenization under 1000 bar pressure for 4 times, and sterilized by filtration with a 0.22 μm microporous membrane. The encapsulation efficiency, particle size distribution and dispersion index (PDI) of burnet aglycone in liposomes were measured, and the results are shown in Table 1.

[0043] Table 1 Quality Evaluation of Burnet Aglycone Liposomes

[0044]

[0045] Note: Compared with HSPC:DSPE-PEG 2000:cholest...

experiment example 2

[0049]The influence of experimental example 2 carrier material dosages on the quality of burnet aglycone liposome

[0050] There are 7 experimental groups in this experiment.

[0051] Weigh burnet aglycone and total lipid (HSPC:DSPE-PEG2000:cholesterol=5:1:1) according to the mass ratio shown in Table 2 respectively (fixed burnet aglycone mass is 1mg, total lipid mass varies with Ratio change), dissolved in ethanol, removed by rotary evaporation under reduced pressure, added 5mg of sucrose and water, so that the concentration of eucalyptin in the liposome suspension was 0.2mg / mL, high pressure homogenization under 1000bar pressure 4 times, Sterilize by filtration with 0.22μm microporous membrane. The encapsulation efficiency, average particle size and dispersion index (PDI) of burnet aglycone in liposomes were measured, and the results are shown in Table 2.

[0052] Table 2 Quality Evaluation of Burnet Aglycone Liposomes

[0053]

[0054] Note: Compared with the 1:20 gro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
The average particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention discloses a sanguisorba officinalis aglycone lipidosome, which is prepared from the following raw and auxiliary materials in proportion by weight: 1 part of sanguisorba officinalis aglycone and 2 to 40 parts of carrier materials, wherein the carrier materials are prepared from hydrogenated soybean phospholipids, distearoyl phosphoethanolamine-polyethyleneglycol 2000 and cholesterin according to a weight ratio of 5:(1 to 4):(1 to 2). The invention also provides a preparation method and a purpose of the lipidosome. The lipidosome has the advantages that the number of peripheral blood leucocytes, neutrophilic granulocytes, red cells, blood platelets, hemoglobin and bone marrow hematopoietic stem cells can be obviously increased; and the obvious effects of treating and / or preventing bone marrow suppression are achieved.

Description

technical field [0001] The invention relates to a eucharin liposome, a preparation method and application thereof, and belongs to the field of medicine. Background technique [0002] Myelosuppression is a clinically common hematopoietic system disease, which can occur in radiotherapy and / or chemotherapy of tumor diseases of various systems, radiation injury caused by ionizing radiation, viral hepatitis, parvovirus infection or drugs (chloramphenicol , benzene, sulfonamides, antiepileptics, sedatives, antithyroid drugs, antidiabetics, antimalarials, sleeping pills) and other factors. Bone marrow suppression can cause damage to the bone marrow microenvironment, hematopoietic stem cells, hematopoietic growth factors, etc., and the first, second or third lineage of granulocytes, erythrocytes, and megakaryocytes are inhibited. Agranulocytosis can cause serious infection; red blood cell decrease can cause severe anemia; platelet decrease can cause severe bleeding and even death. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/127A61K47/24A61K47/28A61K31/56A61P7/00A61P35/00
CPCA61K9/1273A61K9/1277A61K31/56A61K47/24A61K47/28
Inventor 杨世林
Owner SICHUAN YINGLU WEITE PHARMA TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com